You are here: Industry Insights > Psoriasis

News List

FDA and EMA accept regulatory submissions for UCB’s bimekizumab pharmatimes
September 27, 2020
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both accepted marketing application submissions for UCB’s psoriasis treatment bimekizumab.
FDA Approves STELARA for Pediatric Patients with Moderate to Severe Plaque Psoriasis americanpharmaceuticalreview
August 11, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for STELARA® (ustekinumab) as a treatment for pediatric patients (6-11 years of age) with the skin les
Cosentyx wins EU approval for first-line paediatric psoriasis pharmatimes
August 04, 2020
Novartis’ Cosentyx (secukinumab) has been granted approval by the European Commission as a treatment for moderate-to-severe plaque psoriasis in children and adolescents aged six to <18 years.
US expands scope of Janssen's Stelara pharmatimes
August 04, 2020
Janssen's Stelara (ustekinumab) has been approved in the US as a treatment for paediatric patients (six-11 years of age) who struggle with the skin lesions or plaques associated with moderate to severe plaque psoriasis.
DCGI approves Itolizumab for restricted emergency use in COVID-19 treatment expresspharma
July 13, 2020
The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by an expert committee, informed the drug regulator.
Lipidor and Cadila Pharma strike partnership for psoriasis drug candidate’s phase III clinical study expresspharma
July 08, 2020
The Phase III study is expected to involve 270 patients and will be conducted in India on patients with various skin types.
Lipidor, Cadila Sign Agreement for Phase III Trial of AKP-02 contractpharma
July 08, 2020
Cadila Pharmaceuticals to conduct a Phase III study for Lipidor's anti-psoriasis candidate AKP-02.
International Psoriasis Council Statement On The Coronavirus (COVID-19) Outbreak PRNewswire
March 13, 2020
The rapid spread of the coronavirus (COVID-19) is a serious public health concern. It remains unknown to what extent the coronavirus impacts psoriasis and the treatment of psoriasis.
Dermavant sells Tapinarof commercial rights in Japan pharmaceutical-technology
January 19, 2020
Dermavant Sciences, a subsidiary of Roivant Sciences, has signed an exclusive agreement to sell the development and commercial rights of tapinarof in Japan.
DURECT Announces Top-Line Results from Psoriasis Clinical Trial americanpharmaceuticalreview
January 03, 2020
DURECT announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study ...

Previous page 1 2 3 4 5 6 7 8 9 10 Next page